David Sinclair Longevity: Press Coverage, Statements, and What He Takes

Who Is David Sinclair and Why Does His Coverage Matter?

David Sinclair, PhD, AO, holds the Gordon and Betty Moore professorship at Harvard Medical School and runs one of the most-cited aging-biology laboratories in the world. His 2019 book "Lifespan" sold over one million copies and pulled longevity science into mainstream awareness. When he discloses his own supplement stack in interviews or on social media, product sales move within hours. That commercial ripple effect makes accurate, sourced coverage of his statements a genuine public-health concern, not a celebrity trivia exercise.

His Scientific Standing

Sinclair's lab has published more than 200 peer-reviewed papers. His 2013 Cell paper on NAD+ and sirtuin activation (PMID 24360282) is cited over 3,000 times and remains one of the foundational studies linking NAD precursor supplementation to mitochondrial function in aging mice. He is also a co-investigator on the TAME trial, the first study to seek FDA approval using aging itself, rather than a specific disease, as a primary indication.

The Gap Between the Lab and the Clinic

A repeated theme in press coverage is the distance between Sinclair's rodent and cell-line data and the human evidence base. Sinclair himself acknowledged this in a 2023 interview on the Huberman Lab podcast: "I take these things because I believe the animal data is compelling enough for me personally to act on, but I don't recommend others do the same without talking to their doctor." That statement is worth keeping in view when evaluating any downstream media claims about his regimen.

What David Sinclair Says He Takes: A Source-by-Source Breakdown

Sinclair has disclosed his personal regimen across multiple public venues, including his own podcast "Lifespan with David Sinclair," the Joe Rogan Experience (episodes 1234 and 1670), the Huberman Lab podcast, and his 2019 book. The regimen has evolved over time, and some items have been added or dropped as new data appeared.

NMN (Nicotinamide Mononucleotide)

Sinclair stated in his book and in multiple podcast appearances that he takes 1,000 mg of NMN each morning, typically mixed in yogurt. NMN is a precursor to NAD+, a coenzyme central to sirtuin activity and mitochondrial energy production. He has described his rationale as based primarily on the work published by his lab and by Shin-ichiro Imai's group at Washington University.

A 2023 placebo-controlled trial published in Nature Aging (PMID 36604431, N=80) found that 12 weeks of NMN at 300 mg/day raised blood NAD+ levels significantly compared with placebo (P<0.001) but did not produce statistically significant changes in insulin sensitivity or muscle function. Sinclair has cited early-phase human pharmacokinetic data as reason enough to continue, while acknowledging that large-scale efficacy trials are still underway. [1]

Resveratrol

Sinclair takes 1,000 mg of resveratrol daily, mixed with a fat source (usually yogurt) to improve bioavailability. He co-authored the landmark 2003 Nature paper showing resveratrol activates SIRT1 in yeast, extending replicative lifespan (PMID 12960000). [2] That finding generated enormous commercial interest in resveratrol supplements.

Subsequent human trials have been less consistent. A 2012 JAMA Internal Medicine study (PMID 22710741, N=119) found that resveratrol supplementation did not significantly improve cardiovascular risk markers in older adults over 12 months. Sinclair has publicly acknowledged these trials but argues that bioavailability issues and dosing differences limit their interpretability. [3]

Metformin

Sinclair has disclosed taking metformin 1,000 mg at night, sometimes described as 1,000 to 2,000 mg depending on the interview. Metformin is an FDA-approved biguanide for type 2 diabetes. Its proposed longevity mechanism involves AMPK activation and mTOR inhibition, pathways associated with caloric-restriction mimicry.

The TAME trial, launched by the American Federation for Aging Research (AFAR) and currently enrolling at 14 US sites, will follow 3,000 adults aged 65 to 79 over six years to determine whether metformin delays the onset of age-related diseases as a composite endpoint. This is the first time the FDA has agreed that aging itself can serve as a trial endpoint. Sinclair serves as a scientific advisor to the project. [4]

Metformin's long-term safety data in non-diabetic adults remains limited. A 2020 Nature Aging commentary noted that metformin may blunt some exercise-induced metabolic adaptations, which is a real consideration for anyone physically active. [5]

Quercetin, Spermidine, and Other Agents

In more recent interviews (2022 onward), Sinclair added quercetin (a senolytic candidate) and spermidine (a polyamine that may stimulate autophagy) to his public disclosures. He has been explicit that human evidence for these agents is even thinner than for NMN or resveratrol and that their inclusion reflects his personal risk-benefit calculus.

He has also described taking vitamin D3 (4,000 to 5,000 IU/day), vitamin K2, low-dose aspirin (83 mg), and omega-3 fatty acids, though he noted in a 2023 X (formerly Twitter) post that he paused aspirin after reviewing updated bleeding-risk data from the ASPREE trial (PMID 29979388, N=19,114), which found no net benefit in healthy older adults. [6]

How the Press Has Covered Sinclair's Statements

Coverage of Sinclair falls into three broad camps: uncritical amplification, measured science journalism, and pointed peer criticism. All three are worth understanding.

Uncritical Amplification

Outlets ranging from Men's Health to mainstream financial media have published regimen listicles that strip Sinclair's hedging language and present NMN or resveratrol as proven anti-aging agents. Sinclair has publicly objected to some of this framing. In a 2022 tweet, he wrote: "I take these supplements because the animal data is compelling, not because human trials are complete. Please don't read my choices as medical advice."

The distinction matters because none of these agents are FDA-approved for longevity or aging indications. Readers who see a Harvard professor's name attached to a product and assume regulatory validation are working from a false premise.

Measured Science Journalism

The New York Times, STAT News, and MIT Technology Review have all produced nuanced profiles distinguishing Sinclair's research contributions from the evidence base for his personal regimen. A 2023 STAT News piece quoted endocrinologist Dr. Eric Verdin, president of the Buck Institute for Research on Aging, noting that "the NAD field is genuinely exciting, but we are years away from knowing whether raising NAD in humans produces the lifespan or healthspan changes we see in mice."

Peer Criticism: The Kaeberlein Debate

Matt Kaeberlein, PhD, former director of the University of Washington Healthy Aging and Longevity Research Institute, has been the most consistent public critic of Sinclair's communication style. In a 2022 podcast appearance on "The Longevity Podcast" and in written commentary, Kaeberlein argued that Sinclair overstates the human applicability of sirtuin and resveratrol data and that the commercial ventures Sinclair has co-founded create conflicts of interest that are underreported in popular media.

Sinclair disclosed his financial interests in his book's endnotes and on his lab's website. Whether that level of disclosure is sufficient given his mainstream media reach is a legitimate ongoing debate in research-ethics circles.

The Science Sinclair's Work Is Built On

Sirtuins and the Information Theory of Aging

Sinclair's overarching hypothesis, described in detail in "Lifespan," proposes that aging is primarily a loss of epigenetic information rather than an accumulation of DNA mutations. The central actors in this model are sirtuins, a family of seven NAD-dependent deacylase enzymes (SIRT1 through SIRT7) that regulate gene expression, DNA repair, and metabolic adaptation.

When DNA breaks occur (from radiation, chemical damage, or normal replication errors), sirtuins leave their usual gene-regulatory posts to assist with repair. This "distraction," Sinclair argues, causes epigenetic drift, the gradual dysregulation of gene expression patterns that may underlie many hallmarks of aging. [7] A 2023 Cell paper from his lab (PMID 36580946) demonstrated that inducing epigenetic reprogramming via Yamanaka factors could restore vision in aged mice, a finding that generated substantial press coverage and peer excitement alike. [8]

NAD+ Decline as a Target

NAD+ levels fall with age in most tissues studied. Sinclair's 2013 Cell paper (PMID 24360282) showed that restoring NAD+ in 22-month-old mice (roughly equivalent to a 70-year-old human) using the precursor NMN improved mitochondrial function to levels resembling 6-month-old mice within one week. [1] That paper is the scientific anchor for much of his public advocacy around NMN supplementation.

The key limitation is that mice metabolize NMN differently than humans, and the doses used in mouse studies, when scaled to body weight, would correspond to far larger human doses than the 1,000 mg Sinclair takes. Whether the biomarker improvements seen in short human pharmacokinetic trials translate to longevity outcomes is not yet established.

Epigenetic Reprogramming: The Frontier

The most forward-looking strand of Sinclair's current work involves partial epigenetic reprogramming, resetting cells toward a younger epigenetic state without reverting them to a fully undifferentiated (and potentially tumorigenic) state. His lab's optic-nerve reprogramming study, published in Nature in 2020 (PMID 32559391, N=mouse model), showed that AAV-delivered Yamanaka factors restored youthful gene expression patterns and improved visual acuity in aged and glaucoma-model mice. [9]

Human clinical applications are years away. Sinclair has been candid in interviews that he does not expect these therapies to be available outside of trials for at least a decade. Press coverage sometimes collapses that timeline, and Sinclair has had to correct overly optimistic headlines on his own social channels.

Conflicts of Interest and Disclosure: What the Coverage Often Misses

Sinclair co-founded or holds equity in a reported 14+ biotech companies as of his 2019 book disclosures, including Life Biosciences (focused on aging sub-programs), InsideTracker (blood-biomarker testing), and EdenRoc Sciences. He is also a scientific co-founder of Jumpstart Fertility and several other ventures. These relationships are disclosed in academic papers and in his book, but they are frequently absent from popular-media profiles.

A useful framework for readers evaluating his press appearances:

1. Is the claim tied to a peer-reviewed publication from an independent group, or solely from his own lab?
2. Does the commercial product he mentions (or that is marketed using his name) align with a company in which he holds equity?
3. Has the claim been reproduced in humans, or does it rely on animal models only?
4. Does Sinclair's own language in the original interview include hedges that were removed in the published story?

Applying these four questions to most popular coverage of Sinclair will clarify which claims rest on solid ground and which remain speculative.

Clinical Takeaways for Patients Asking About Sinclair's Regimen

Patients who arrive at a telehealth or primary care visit citing Sinclair's protocol deserve accurate, non-dismissive guidance. The following represents a clinically grounded summary of each major agent.

Metformin in Non-Diabetic Adults

Metformin is the most clinically interesting item on Sinclair's list because it has the longest human safety record and a plausible mechanism. Prescribing it off-label for longevity is legal in the United States but not guideline-supported. The American Diabetes Association 2024 Standards of Care do not endorse metformin for aging indications. [10] The TAME trial results, expected around 2027 to 2028, will be the first adequately powered human test of this hypothesis.

Clinicians should check renal function (eGFR <30 mL/min/1.73m² is a contraindication), B12 levels (metformin reduces B12 absorption over time), and lactate in at-risk patients before initiating any off-label use.

NMN and Other NAD Precursors

NMN and its cousin NR (nicotinamide riboside) are generally considered safe at commonly used doses based on phase-one data. A 2022 randomized controlled trial of NR at 1,000 mg/day in healthy older adults (PMID 34385400, N=30, 21 days) found NAD+ rises in blood but no significant change in skeletal-muscle NAD+ or mitochondrial function. [11] Patients interested in trying these agents should be advised that they are buying a pharmacokinetic effect (rising blood NAD+) whose downstream clinical significance in humans has not been established.

Resveratrol

The bioavailability problem with resveratrol is well-documented. Oral resveratrol is rapidly metabolized, and peak plasma concentrations after a 1,000 mg dose rarely exceed 1 micromolar, well below concentrations used in cell studies. Sinclair's approach of co-ingesting it with dietary fat may modestly improve absorption. Patients with a history of hormone-sensitive conditions should note that resveratrol has weak estrogenic activity at some concentrations in vitro.